AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05396625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: All participants will receive the following services: case management and psychosocial support (e.g., assessment and identification of families eligible for reunification; preparing children and parents for reunification; and assistance with receiving social benefits such as Targeted Social Assistance, alimonies, or disability benefits); referrals to schools outside of their orphanage; and leisure activities for children (e.g., music, sport, and drama) provided by the orphanage staff and municipal social services.
Study NCT05396625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Strengthening
Description: Due to its focus on family-strengthening, the study uses the evidence-based intervention, SAFE Children, which employs a multiple family group format and is designed to improve family functioning, strengthen child-parent relationships and communication, enhance supportive parenting strategies, and prevent emotional and behavioral problems among at-risk children. The family-focused intervention consists of weekly multiple family group meetings (e.g. about 5 families per group). All interested family members are invited to join the sessions. The adapted intervention incorporates new sessions that address unique issues faced by families reuniting with formerly institutionalized children, such as, separation and attachment issues, children's feelings of resentment, parents' feelings of guilt and shame, stigmatized status in the community. Each session lasts about one to one and a half hours and delivered by facilitator and co-facilitator at the SOS Child and Family Center.
Study NCT05396625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Health Screening, Referral and Connection to Services
Description: Children assigned to this intervention will receive clinical assessment performed by psychiatrists at the National Mental Health Centre in Azerbaijan. From there, each child will have an individual plan developed by the multidisciplinary team and will be connected to the National Mental Health Centre clinicians to receive corresponding mental health services.
Study NCT05396625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Economic Empowerment
Description: The economic component will be in the form of Child Development Accounts/CDAs, an asset-based strategy encouraging savings and investment. This component will connect families to a bank and train them on how to save small amounts, which will be matched by contributions from the project. Matched savings will be deposited in a separate account and can be used only towards a child's education or for housing. The project will provide $50 as seed money to open a savings account in the child's name. The child's family members will make small monthly contributions to the CDA, and savings of up to $20 per month will be matched with project funds at a rate of 2:1. Caregivers will also receive training on savings and financial planning. The curriculum will be taught by trainers from the SOS in a group format for 5 sessions and will cover these topics: The Importance of Saving; Identifying and Managing Resources; Setting Up a Savings System; Sources of Income; and Budgeting and Spending.
Study NCT05821309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 3350
Description: The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
Study NCT05821309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-3350 with electrolytes
Description: The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
Study NCT05821309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerin
Description: Glycerin will be given to patients based on standard of care, at the discretion of the pediatric gastroenterology and pediatric surgery teams. Glycerin administration will not be randomized. For secondary analysis, the microbiomes of those who have and have not received glycerin will be compared.
Study NCT05629702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabiximols
Description: Oromucosal spray
Study NCT05629702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral capsule
Study NCT05629702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide
Description: Oral capsule
Study NCT05629702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nabiximols-matched placebo
Description: Nabiximols-matched placebo oromucosal spray
Study NCT05499637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PentixaFor PET/CT
Description: \[68Ga\]Ga-PentixaFor PET/CT
Study NCT06008691 — intervention group
Intervention type: DRUG
Intervention: novel MAB (alone or in combination)
Description: novel MAB (alone or in combination) based on presence of an EMA clinical indication since 2020 and prescribed according to the indications for use authorized for marketing in Italy
Study NCT05823259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid Telehealth Program: Respiratory Muscle Training and Patient Education
Description: A testing session will be held where subjects will undergo respiratory muscle testing using the Pro2Fit device to measure PIMax and PEmax. During this session, subjects will be instructed in a respiratory muscle training home program utilizing a provided device call the Breather. They will be instructed to perform this program consisting of breathing exercises for 2 sets of 10 repetitions, twice a day at a difficulty level of 5-7 on the Visual Analogue Scale (VAS) scale for 8 weeks. Subjects will be shown how to follow a training program every day utilizing the free companion application to the device Breather Coach. If subjects have issues with using technology, they will be provided a physical log to record when they complete sessions. Ten to fifteen-minute Zoom sessions with the study coordinator will be held once a week to check in on how the program is progressing, compliance, and if the resistance can be increased.
Study NCT05823259 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy Care
Description: A group of patients who receive standard physical therapy care for chronic constipation at the University of Miami that consists of biofeedback therapy, manual therapy, therapeutic exercise, and patient education.
Study NCT06353841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times a week in four weeks.
Study NCT06433908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol HFA-152a
Description: 100 µg (ex-valve), given at 20-second intervals.
Study NCT06433908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol HFA-134a
Description: 100 µg (ex-valve), given at 20-second intervals.
Study NCT06340906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: EA at 10 standardized acu-points that were chosen for their therapeutic effects: Zhongwan (CV12), Guanyuan (CV4), Neiguan (PC6), Shenmen (HT7), Hegu (LI4) bilateral, Zusanli (ST36), Sanyinjiao (SP6), Zhaohai (KI6), Taichong (LR3) bilateral, Tian Shu (ST25) bilateral.
Study NCT06423703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol
Description: once daily for 3 days
Study NCT06423703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone IR
Description: four times per day for 3 days
Study NCT06423703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: three times per day 3 days (with cebranopadol), four times per day for 3 days (placebo arm)
Study NCT06423703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: three times per day 3 days (with cebranopadol), four times per day for 3 days (placebo arm)
Study NCT05597969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FoodCoach
Description: The FoodCoach app displays transparent analysis and recommendations regarding participant's food purchases recorded on their loyalty cards. It tries to help participants understand why and how they should/can shop more healthily, motivating them to change their unhealthy food purchase behavior.
Study NCT06302751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Care 4 Today ® (Johnson and Johnson) mobile app
Description: Care 4 Today ® (Johnson and Johnson) mobile app will cover the perioperative period spanning through the preoperative assessment day (approximately -seven to -one from surgery) to 30 days after surgery and will monitor the adherence to preoperative and postoperative recommendations.
Study NCT05891002 — intervention group
Intervention type: DEVICE
Intervention: Cirq® Robotic Alignment Module Cranial
Description: Robotic navigation for cranial biopsy procedure
Study NCT06213532 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking Cessation Intervention
Description: Multimedia program administered either remotely or in person
Study NCT06213532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Multimedia program administered either remotely or in person
Study NCT06213532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Intervention
Description: Multimedia program administered either remotely or in person
Study NCT06213532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva Collection
Description: Saliva samples will be collected from each participant
Study NCT06213532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saliva Collection
Description: Saliva samples will be collected from each participant
Study NCT06213532 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06213532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06213532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05609370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007
Description: Administered intravenously.
Study NCT05609370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LBL-007
Description: Administered intravenously.
Study NCT05609370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously.
Study NCT05609370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: Administered intravenously.
Study NCT05609370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab or Bevacizumab biosimilar
Description: Administered intravenously
Study NCT05609370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab or Bevacizumab biosimilar
Description: Administered intravenously
Study NCT05609370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered in accordance with relevant local guidelines and/or prescribing information
Study NCT05609370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Administered in accordance with relevant local guidelines and/or prescribing information
Study NCT05609370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Administered in accordance with relevant local guidelines and/or prescribing information
Study NCT05609370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Administered in accordance with relevant local guidelines and/or prescribing information
Study NCT04747613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iptacopan
Description: Taken orally b.i.d. Dosage supplied: 200 mg Dosage form: hard gelatin capsule Route of administration: oral
Study NCT05927350 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey asking about sociodemographics, pediatric research participation, experience with research, gender minority stress and resilience, vaccine hesitancy, medical mistrust, and connectedness to the LGBT community
Study NCT05287321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200mg with Aspirin 100mg
Study NCT05339529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-
Description: Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead.
Study NCT05339529 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Blank control
Description: Blank control
Study NCT05842408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5212
Description: Test drug: DA-5212
Study NCT05842408 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DA-5212-R
Description: Control drug: DA-5212-R
Study NCT06213454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAP Anesthesia
Description: ultrasound guided TAP block, 133 mg of liposomal bupivacaine and 15 mL of 0.25% bupivacaine deposited into the TAP on each side for a total of two injections
Study NCT06213454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Surgeon-Initiated Local Anesthetic
Description: 266 mg of liposomal bupivacaine and 30 mL of 0.25% bupivacaine diluted in 130 mL of normal saline (160 mL of solution), 40 mL fascial injection and 40 mL skin injection on either side of the wound
Study NCT05195645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept 250 MG
Description: Abatacept will be administered by intravenous injection over 1h15 to 2h30 on D1, D5+/-2 and D14+/-2 at 10mg/kg (arm A), or 20mg/kg (arm B) or 25mg/kg (arm C) depending on the randomization (max 3 000 mg per administration). Starting Day 21 (after evaluation of the primary outcome), other injection of abatacept may be given (D22 at D90) with dosage (10 or 20mg/kg max) decided by the treating physician (max 2 500 mg per administration) as a function of the relapse or not of the ICI myocarditis after immunosuppressant therapeutics tapering. After day 21, the administrations will be carried out in open but the blind administration 1 to 3 (D1 to D21) will be kept.
Study NCT04118530 — intervention group
Intervention type: OTHER
Intervention: HSCT Patients
Description: Prospective, observational review of incidence of AF/AFL through Carelink remote monitoring and safety of implantation of device in this population of patients through review of standard of care follow up visits post HSCT implant
Study NCT05671848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recordings of thalamic activity
Description: Recordings of thalamic activity will be performed at home, in ecological conditions. They will be realized during 4 distinct conditions each week between M3 and M6 post implantation: at rest and during tremor-induced movements. For these recordings, stimulation will be either turned Off or On. Three successive recordings of 30 seconds separated by 1 minute will be made for each condition.
Study NCT06348238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Affirmation
Description: Self-affirmation theory contends that integrity of one's self-concept (self integrity) is essential for navigating daily stressors. When individuals encounter information or contexts that pose a threat to one's self-integrity, we can adopt maladaptive coping strategies to alleviate the discomfort. One strategy for strengthening self-integrity is engage in an explicit process of reinforcing sources of self-worth - self-affirmation. Self affirmation interventions have participants engage in an exercise writing about core personal values (a writing induction). In a writing induction, participants review a list of values and are instructed to choose up to two that are important to them. Participants are then asked to write a few sentences about why their chosen values are important to them and identify times in which these values have helped them navigate challenges.
Study NCT06348238 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Self-Affirmation
Description: Self-affirmation theory contends that integrity of one's self-concept (self integrity) is essential for navigating daily stressors. When individuals encounter information or contexts that pose a threat to one's self-integrity, we can adopt maladaptive coping strategies to alleviate the discomfort. One strategy for strengthening self-integrity is engage in an explicit process of reinforcing sources of self-worth - self-affirmation. Self affirmation interventions have participants engage in an exercise writing about core personal values (a writing induction). In a writing induction, participants review a list of values and are instructed to choose up to two that are important to them. Participants are then asked to write a few sentences about why their chosen values are important to them and identify times in which these values have helped them navigate challenges.
Study NCT06315075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy for adolescents (DBT-A)
Description: A 20-week DBT-A with a weekly individual session (45 minutes), a weekly session of multifamily skills training groups with a caregiver (120 minutes), and telephone consultation with individual therapists outside therapy sessions as needed. The treatment consists of four components and is delivered according to the manual except for the phone coaching that PBU offers workdays until 8 pm.
Study NCT06283472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Cue
Description: Participants in the high-intensity group will receive high-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
Study NCT06283472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity Cue
Description: Participants in the low-intensity group will receive low-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
Study NCT05305664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelacarsen (TQJ230) 80 mg s.c.
Description: Pelacarsen (TQJ230) 80 mg s.c. Q4W
Study NCT05305664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corresponding Placebo
Description: Placebo to Pelacarsen
Study NCT06386315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT06386315 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT06386315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Procedure
Description: Undergo endoscopy
Study NCT06386315 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Procedure
Description: Undergo endoscopy
Study NCT06386315 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-site Radiation Therapy (3 Fractions)
Description: Undergo ISRT in 3 fractions
Study NCT06386315 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Involved-site Radiation Therapy (12 Fractions)
Description: Undergo ISRT in 12 fractions
Study NCT06386315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06386315 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06386315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06386315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05799755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib
Description: Nintedanib 150 mg BID
Study NCT05799755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nintedanib
Description: Nintedanib 150 mg BID
Study NCT05799755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT05799755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Maximum of 2 standard of care immunosuppressant (IS) drugs are allowed, one being a glucocorticoid (GC) and the other being a non-GC IS drug OR 2 non-GC IS drugs in the event that the patient is not on a GC). The patient should be on the IS drug(s) for at least 12 weeks (at least 4 weeks or more for GC) before the screening. The doses should be stable for at least 4 weeks (at least 2 weeks for GC) before the screening visit.